Study 7: HOPE-IPF

Principal Investigator

Dr. Parameswaran Nair


Some patients with chronic obstructive pulmonary diseases (COPD) have large numbers of specific white blood cells called "eosinophils" in their airways. These cells are also responsible for causing episodes of worsened respiratory symptoms (exacerbations) and often cause irreversible damage to the airways. Mepolizumab is a drug that specifically targets eosinophils reducing the number in the airway. This drug has been shown to be effective in decreasing exacerbation rates and time to exacerbation in asthma patients with eosinophils in their airways. Targeting eosinophils in COPD patients has been shown to reduce severe exacerbations. Hence it is likely that COPD patients with eosinophils in their airways will benefit similarly and have reduced rates and time to exacerbation.


A third of patients with severe COPD may have sputum eosinophilia. This study evaluates the efficacy of a monoclonal antibody directed against IL5, mepolizumab, in these patients to decrease exacerbations, improve lung function and quality of life.

For more information about this study please contact study coordinator Melanie Kjarsgaard by e-mail at

Accessibility for Ontarians With Disabilities Act (AODA)


The Faculty of Health Sciences is committed to providing a website that is accessible to the widest possible audience. If there is an accessibility issue with this website, please contact us at